A Prospective, Randomized, Double-blinded Comparison of the Use of 5-fluorouracil Versus Placebo in Periocular Full Thickness Skin Grafts.
The clinical trial sponsored by Massachusetts Eye and Ear Infirmary aims to evaluate the efficacy of 5-fluorouracil (5-FU) in reducing complications associated with periocular full thickness skin grafts. Given the limited options for managing scarring and graft shrinkage in oculofacial surgery, a successful outcome could position 5-FU as a novel adjunct therapy in this niche market. The potential to enhance patient satisfaction and reduce the need for corrective surgeries could lead to significant adoption among ophthalmic surgeons. However, challenges in patient recruitment may hinder the trial's robustness and subsequent market entry. Competitive analysis reveals that while corticosteroids are currently the standard treatment, 5-FU could offer a safer alternative with fewer side effects, particularly in sensitive periocular applications.
Indication: Ectropion
Modality: small molecule
Target: Thymidylate synthetase (inhibition by 5-fluorouracil)
Sponsor: Massachusetts Eye and Ear Infirmary
Source URL: ClinicalTrials.gov
Source updated: Mar 09, 2020
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Thymidylate synthetase (inhibition by 5-fluorouracil)
View original source fields
Condition raw: Ectropion, Skin Neoplasms
Condition normalized: Ectropion, Skin Neoplasms
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Thymidylate synthetase (inhibition by 5-fluorouracil)
Target normalized: Thymidylate synthetase (inhibition by 5-fluorouracil)